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Is Less More?
Dual- Versus Single-Chamber
Implantable Cardioverter-Defibrillators*
Amin Al-Ahmad, MD,
James V. Freeman, MD, MPH
Stanford, California
In this issue of the Journal, Dewland et al. (1) use the
ational Cardiovascular Data Registry (NCDR) Implant-
ble Cardioverter-Defibrillator (ICD) Registry to evaluate
he rate of in-hospital complications and death in patients
ho receive dual-chamber compared with single-chamber
CDs. As the investigators point out, most of the clinical
rials evaluating ICD efficacy have included only single-
hamber devices or relatively few dual-chamber devices.
he main exception to this was MADIT II (Multicenter
utomatic Defibrillator Implantation Trial II), in which
ual-chamber devices were implanted in approximately
ne-half of the study participants, and no difference was
een in survival between the 2 types of devices over the
ourse of the study period (2,3). Dewland et al. (1) show
hat in their study population from the NCDR ICD
egistry, which is generally representative of the U.S.
ational experience, currently almost twice as many dual-
hamber ICDs are placed as single-chamber devices. Dual-
hamber ICDs cost more than single-chamber ICDs, and
lacement of the atrial lead may involve longer procedure
ime and higher risk. Therefore, it is worthwhile to establish
hether there are advantages in terms of efficacy, as well as
isadvantages in terms of safety, with these devices.
See page 1007
Dewland et al. (1) report that 40.4% of dual-chamber
ICD recipients in their study fulfilled a Class I or IIa
indication for cardiac pacing from the 2008 American
College of Cardiology, American Heart Association, and
Heart Rhythm Society guidelines for device-based therapy
of cardiac rhythm abnormalities and were appropriate for
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Physician Round Table-Spina Outcomes Research Fellowship.dual-lead devices (4). However, there are Class I and IIa
indications for cardiac pacing that the investigators did not
include in their list of appropriate indications, including
patients with unexplained syncope when causes other than
atrioventricular block or sinus node dysfunction have been
excluded or patients with alternating bundle branch block.
As they also point out in their discussion, dual-chamber
devices are often placed for discrimination between su-
praventricular and ventricular arrhythmias to avoid inappro-
priate shock, an important cause of morbidity in ICD
patients. Although data that compare single- with dual-
chamber ICDs in the prevention of inappropriate therapy
have been mixed, more recent data have suggested an overall
clinical benefit in terms of arrhythmia discrimination and
inappropriate shock prevention with dual-chamber devices
(5–7). The advantage of dual-chamber ICDs in arrhythmia
discrimination is likely to be particularly pronounced in
those with histories of supraventricular tachycardias such as
atrial fibrillation, which was more common in the dual-
chamber ICD recipients in this study. Thus, even if a
minority of dual-chamber ICD recipients had Class I or IIa
indications for dual-chamber pacing, it is important to
emphasize that many of these patients may have had a need
for enhanced arrhythmia detection, which can have signif-
icant clinical benefits. Unfortunately, because the NCDR
ICD Registry currently includes only in-hospital adverse
events and there are no long-term follow-up data, the
investigators were unable to assess the long-term clinical
effectiveness of dual- versus single-chamber ICDs with
regard to outcomes such as inappropriate shocks and mor-
tality in their study population.
Dewland et al. (1) have made an important contribution
to our understanding of the periprocedural safety of dual-
versus single-chamber ICDs. They demonstrated that ad-
verse events were more frequent (3.17% vs. 2.11%,
p 0.001) and that the fully adjusted odds of adverse events
were 40% higher with dual-chamber ICDs, which corrob-
orates previous findings from a Canadian retrospective
cohort study (8). This overall difference was accounted for
largely by significantly higher absolute rates of coronary
venous dissection, hematoma, lead dislodgement, and peri-
cardial tamponade with dual-lead devices. The investigators
also found a statistically significant but small absolute
increase in in-hospital mortality (0.40% vs. 0.23%, p 
0.001), and the fully adjusted odds of death were 45%
higher with dual-chamber ICDs. This finding was driven
largely by a significant higher rate of cardiac arrest (0.31%
vs. 0.23%, p  0.01) with dual-lead devices.
These findings are important and of great clinical inter-
est, but they must be viewed in the context of important
caveats. First, the patients who received dual-lead ICDs in
this study were significantly older (mean age 67.1 years vs.
64.0 years, p  0.0001) and they had significantly higher
ates of multiple comorbidities, including syncope (24.6%
s. 17.6%, p  0.0001), nonsustained ventricular tachycar-
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August 30, 2011:1014–5 Single- Versus Dual-Chamber ICDsdia (27.0% vs. 22.2%), monomorphic sustained ventricular
tachycardia (12.5% vs. 8.3%), sinus node dysfunction
(27.5% vs. 16.2%, p  0.0001), and ischemic heart disease
68.8% vs. 65.2%, p 0.0001). Although Dewland et al. (1)
djusted for these and other comorbidities to the greatest
xtent possible using the data available in the NCDR ICD
egistry, given the consistent trend toward increased mor-
idity in the dual-chamber ICD recipients and the small
bsolute differences found particularly for cardiac arrest and
n-hospital mortality, the possibility of residual confounding
iasing the results against dual-chamber devices is substan-
ial. Second, as the investigators point out, the differences in
he complications between the 2 groups of ICD recipients
uggest that more of the dual-chamber ICD patients were
borted biventricular ICD recipients in whom left ventric-
lar leads could not be placed, and this is corroborated by
he fact that the average QRS duration was significantly
igher in the dual-chamber recipients (114.8 ms vs. 108.8
s, p  0.0001). It is very likely that most of the dual-lead
CD recipients who experienced coronary venous dissection
epresented patients for whom left ventricular lead place-
ent was aborted, and for that reason, the investigators
onducted a secondary analysis excluding those with coro-
ary venous dissection that did not statistically change their
esults; however, it is also possible that failure to place a left
entricular lead could be implicated in other important
omplications that were more common with dual-chamber
evices, including hematoma, lead dislodgement, and peri-
ardial tamponade. The data collected from the NCDR
CD Registry did not allow the investigators to risk adjust
or aborted left ventricular lead placement, and this again
ay have biased the results against dual-chamber ICDs.
Dewland et al. (1) have clearly made a significant contri-
ution to our understanding of the in-hospital safety of
ual- versus single-chamber ICDs, and for implanting
linicians, the possible benefits of an additional lead must be
ounterbalanced by the possible risks to patients. However,
heir results, particularly with regard to in-hospital mortal-
ty, should be viewed in the context of important limitationsnd will need to be externally validated with future studies.
he NCDR ICD Registry will soon be linked to Medicare
ata, allowing some assessment of long-term outcomes, and
e-evaluation of adverse events and mortality for dual-
ersus single-chamber ICDs over a longer time horizon will
e an important area for future investigation.
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